Table 2.
Antiviral activities of BXA and reference compounds against human and avian A(H7N9) viruses in a yield reduction assay in MDCK cells.
| Influenza virus strain | Mean EC90 (nM) ± SD | ||||
|---|---|---|---|---|---|
| Baloxavir acid | Oseltamivir acid | Zanamivir hydrate | Laninamivir | Favipiravir | |
| A/Anhui/1/2013 (H7N9) | 0.79 ± 0.35 | 12.90 ± 4.78 | 22.71 ± 6.42 | 11.58 ± 2.62 | 18,454.53 ± 14,157.33 |
| A/Anhui/1/2013 NA-R292K (H7N9)a | 1.12 ± 0.53 | 142,389.79 ± 6,601.02 | NT c | NT c | 17,025.75 ± 4,221.17 |
| A/duck/Japan/AQ-HE28-3/2016 (H7N9) | 0.62 ± 0.11 | 38.52 ± 18.19 | NT c | NT c | 12,014.40 ± 7,990.32 |
| A/duck/Japan/AQ-HE29-22/2017 (H7N9)b | 0.69 ± 0.29 | 12.89 ± 9.85 | NT c | NT c | 17,191.98 ± 13,933.15 |
| A/duck/Japan/AQ-HE30-1/2018 (H7N3)b | 1.13 ± 0.58 | 27.86 ± 17.98 | NT c | NT c | 18,879.83 ± 13,666.58 |
aVirus generated by reverse genetics. bHighly pathogenic avian influenza virus. cNot tested. Data represent mean ± standard deviation from three independent experiments in MDCK cells.